What is the purpose of this trial?
JTX-2011-101 is a Phase 1/2, open label, dose escalation and expansion clinical study of JTX-2011 alone or in combination with a fixed dose of nivolumab in subjects with advanced solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Ages: 18 years and older
Dates: 04/12/2017 - 05/30/2018
Last Updated: 04/13/2017
Study HIC#: 1606017922